Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab plus chemotherapy versus chemotherapy regimens in CD20-positive non-Hodgkin lymphoma
ChiCTR-TRC-08000108Phase 4Recruiting
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Jan 2003
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone and 1 more in non-Hodgkin lymphoma (NHL) (3 arms), sponsored by Fujian Medical University Cancer Hospital. Primary endpoint: Overall survival. Started Jan 2003; status: recruiting.
02
Drugs
rituximabcyclophosphamidedoxorubicinvincristineprednisone
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on ChiCTR-TRC-08000108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-08000108.